S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Compare Pharmaceutical Stocks

Enter up to ten stock symbols separated by a comma or space (ex. ABBV,BMY,GSK,MCK,MRK).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MCK
McKesson
$246.62
-2.1%
$236.42
$169.34
$256.85
$37.65B0.79879,826 shs1.21 million shs
ABBV
AbbVie
$131.98
-0.8%
$127.60
$101.81
$138.15
$233.23B0.867.81 million shs7.58 million shs
GSK
GlaxoSmithKline
$45.10
+0.5%
$43.29
$33.53
$46.85
$121.44B0.754.41 million shs5.47 million shs
MRK
Merck & Co., Inc.
$79.98
-1.0%
$78.01
$70.89
$91.40
$202.03B0.4913.24 million shs18.45 million shs
BMY
Bristol-Myers Squibb
$63.54
-1.6%
$60.44
$53.22
$69.75
$141.04B0.6412.60 million shs13.27 million shs

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
MCK
McKesson
2.82 of 5 Stars
3.55.02.52.50.6
ABBV
AbbVie
3.06 of 5 Stars
2.44.94.22.51.3
GSK
GlaxoSmithKline
1.52 of 5 Stars
0.03.92.50.01.3
MRK
Merck & Co., Inc.
3.11 of 5 Stars
3.34.53.32.51.9
BMY
Bristol-Myers Squibb
2.65 of 5 Stars
2.34.53.32.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MCK
McKesson
2.92
Buy$277.4212.49% Upside
ABBV
AbbVie
2.87
Buy$141.427.15% Upside
GSK
GlaxoSmithKline
2.11
HoldN/AN/A
MRK
Merck & Co., Inc.
2.63
Buy$92.0715.11% Upside
BMY
Bristol-Myers Squibb
2.56
Buy$66.003.87% Upside

Current Analyst Ratings

Latest KMT, TEX, ARGKF, PSK, and ARNC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
1/20/2022
ABBV
AbbVie
Barclays
Boost Price TargetEqual Weight$118.00 ➝ $133.00
1/18/2022
ABBV
AbbVie
Cowen
Boost Price Target$130.00 ➝ $150.00
1/13/2022
ABBV
AbbVie
Redburn Partners
Initiated CoverageBuy
1/12/2022
ABBV
AbbVie
BMO Capital Markets
Boost Price TargetOutperform$134.00 ➝ $153.00
1/7/2022
MCK
McKesson
Credit Suisse Group
UpgradeNeutral ➝ Outperform$230.00 ➝ $333.00
1/5/2022
ABBV
AbbVie
Mizuho
Boost Price TargetBuy$132.00 ➝ $154.00
1/3/2022
ABBV
AbbVie
Piper Sandler
Boost Price Target$129.00 ➝ $160.00
12/23/2021
MRK
Merck & Co., Inc.
Mizuho
Initiated CoverageBuy$100.00
12/20/2021
MCK
McKesson
Mizuho
Boost Price TargetNeutral$236.00 ➝ $250.00
12/17/2021
MCK
McKesson
Morgan Stanley
Boost Price TargetOverweight$252.00 ➝ $292.00
12/17/2021
ABBV
AbbVie
The Goldman Sachs Group
Initiated CoverageNeutral$113.00
(Data available from 1/22/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MCK
McKesson
$238.23B0.16$24.04 per share10.26$1.10 per share224.20
ABBV
AbbVie
$45.80B5.09$13.25 per share9.96$7.42 per share17.79
GSK
GlaxoSmithKline
$43.79B2.77$3.73 per share12.09$9.92 per share4.55
MRK
Merck & Co., Inc.
$47.99B4.21$7.25 per share11.03$10.04 per share7.97
BMY
Bristol-Myers Squibb
$42.52B3.32$10.88 per share5.84$16.74 per share3.80

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MCK
McKesson
-$4.54B-$30.10N/A11.170.96-1.92%-5,793.16%5.35%2/2/2022 (Confirmed)
ABBV
AbbVie
$4.62B$4.2031.429.372.0613.66%166.05%14.72%2/2/2022 (Confirmed)
GSK
GlaxoSmithKline
$7.38B$2.3619.1113.962.5913.01%26.27%7.13%2/2/2022 (Estimated)
MRK
Merck & Co., Inc.
$7.07B$2.8328.2611.631.6614.64%48.21%16.00%2/3/2022 (Confirmed)
BMY
Bristol-Myers Squibb
-$9.02B-$2.40N/A8.131.06-11.89%43.05%14.24%2/4/2022 (Confirmed)

Latest KMT, TEX, ARGKF, PSK, and ARNC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/4/2022N/A
BMY
Bristol-Myers Squibb
$1.85N/A-$1.85N/AN/AN/A  
2/3/2022N/A
MRK
Merck & Co., Inc.
$1.45N/A-$1.45N/AN/AN/A  
2/2/2022N/A
MCK
McKesson
$5.37N/A-$5.37N/AN/AN/A  
2/2/2022N/A
ABBV
AbbVie
$3.30N/A-$3.30N/AN/AN/A  
10/31/20219/30/2021
MCK
McKesson
$4.66$6.15+$1.49$10.59$63.23 billion$66.58 billion    
10/28/20219/30/2021
ABBV
AbbVie
$3.22$3.33+$0.11$4.88$14.30 billion$14.34 billion    
10/27/2021Q3 2021
GSK
GlaxoSmithKline
$0.80$1.01+$0.21$1.38$11.92 billion$12.51 billion    
10/27/20219/30/2021
MRK
Merck & Co., Inc.
$1.55$1.75+$0.20$1.70$12.32 billion$13.15 billion    
10/26/20219/30/2021
BMY
Bristol-Myers Squibb
$1.92$2.00+$0.08$3.31$11.52 billion$11.62 billion    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MCK
McKesson
$1.880.76%+21.92%N/A 15 Years
ABBV
AbbVie
$5.644.27%+44.85%134.29%50 Years
GSK
GlaxoSmithKline
$2.044.52%+2.94%86.44%N/A
MRK
Merck & Co., Inc.
$2.763.45%+32.66%97.53%12 Years
BMY
Bristol-Myers Squibb
$2.163.40%-8.13%N/A 16 Years

Latest KMT, TEX, ARGKF, PSK, and ARNC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2021
ABBV
AbbVie
quarterly$1.415.14%1/13/20221/14/20222/15/2022
12/13/2021
BMY
Bristol-Myers Squibb
Quarterly$0.543.66%1/6/20221/7/20222/1/2022
10/29/2021
GSK
GlaxoSmithKline
quarterly$0.52344.7%11/18/202111/19/20211/13/2022
11/30/2021
MRK
Merck & Co., Inc.
Quarterly$0.693.71%12/14/202112/15/20211/7/2022
10/28/2021
MCK
McKesson
quarterly$0.470.93%11/30/202112/1/20211/3/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MCK
McKesson
N/A
0.99
0.57
ABBV
AbbVie
5.45
1.01
0.91
GSK
GlaxoSmithKline
0.95
0.81
0.54
MRK
Merck & Co., Inc.
0.64
1.31
1.07
BMY
Bristol-Myers Squibb
1.06
1.47
1.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
MCK
McKesson
85.12%
ABBV
AbbVie
65.36%
GSK
GlaxoSmithKline
11.98%
MRK
Merck & Co., Inc.
71.43%
BMY
Bristol-Myers Squibb
72.11%

Insider Ownership

CompanyInsider Ownership
MCK
McKesson
0.28%
ABBV
AbbVie
0.09%
GSK
GlaxoSmithKline
10%
MRK
Merck & Co., Inc.
0.32%
BMY
Bristol-Myers Squibb
0.11%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
MCK
McKesson
76,000152.68 million152.25 millionOptionable
ABBV
AbbVie
47,0001.77 billion1.77 billionOptionable
GSK
GlaxoSmithKline
94,0662.69 billion2.42 billionOptionable
MRK
Merck & Co., Inc.
74,0002.53 billion2.52 billionOptionable
BMY
Bristol-Myers Squibb
30,2502.22 billion2.22 billionOptionable

KMT, TEX, ARGKF, PSK, and ARNC Headlines

SourceHeadline
Whats Behind Bristol Myers Squibbs Latest Partnership?What's Behind Bristol Myers Squibb's Latest Partnership?
finance.yahoo.com - January 22 at 12:45 PM
Bristol Myers Squibb (BMY) Stock Moves -1.61%: What You Should KnowBristol Myers Squibb (BMY) Stock Moves -1.61%: What You Should Know
finance.yahoo.com - January 21 at 9:02 PM
4 Perfect Dividend Stocks to Buy if Theres a Stock Market Crash4 Perfect Dividend Stocks to Buy if There's a Stock Market Crash
finance.yahoo.com - January 20 at 7:50 AM
Bristol Myers Squibb (BMY) Stock Moves -0.26%: What You Should KnowBristol Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know
entrepreneur.com - January 19 at 7:23 PM
Senate Finance chair investigates Bristol Myers over an allegedly abusive overseas tax shelterSenate Finance chair investigates Bristol Myers over an allegedly abusive overseas tax shelter
statnews.com - January 19 at 9:22 AM
Brain Tumor Therapeutics Market to Record 9.10% Y-O-Y Growth Rate in 2021 | Amgen Inc. and Bristol-Myers Squibb Co. Among Key Vendors | TechnavioBrain Tumor Therapeutics Market to Record 9.10% Y-O-Y Growth Rate in 2021 | Amgen Inc. and Bristol-Myers Squibb Co. Among Key Vendors | Technavio
prnewswire.com - January 19 at 3:54 AM
HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...
finance.yahoo.com - January 18 at 2:08 PM
Gilman Hill Asset Management, LLC Buys Star Bulk Carriers Corp, The Western Union Co, JetBlue ...Gilman Hill Asset Management, LLC Buys Star Bulk Carriers Corp, The Western Union Co, JetBlue ...
finance.yahoo.com - January 18 at 9:47 AM
What Botswana Can Teach the World About Solving a Health CrisisWhat Botswana Can Teach the World About Solving a Health Crisis
finance.yahoo.com - January 18 at 9:08 AM
Looking Into Bristol-myers Squibb Companys Recent Short InterestLooking Into Bristol-myers Squibb Company's Recent Short Interest
msn.com - January 14 at 2:23 PM
HighTower Trust Services, LTA Buys Amazon. ...HighTower Trust Services, LTA Buys Amazon. ...
finance.yahoo.com - January 14 at 2:23 PM
4 Biotech Acquisitions Wed Like to See in 20224 Biotech Acquisitions We'd Like to See in 2022
finance.yahoo.com - January 14 at 8:54 AM
Inside the deal: Why Century Therapeutics picked Bristol Myers Squibb for its first Big Pharma mega-dealInside the deal: Why Century Therapeutics picked Bristol Myers Squibb for its first Big Pharma mega-deal
finance.yahoo.com - January 14 at 8:54 AM
Bristol Myers Squibb (BMY) Stock Moves -0.34%: What You Should KnowBristol Myers Squibb (BMY) Stock Moves -0.34%: What You Should Know
finance.yahoo.com - January 13 at 8:50 PM
Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...
finance.yahoo.com - January 12 at 9:45 AM
Kohmann Bosshard Financial Services, LLC Buys Global X U.S. ...Kohmann Bosshard Financial Services, LLC Buys Global X U.S. ...
finance.yahoo.com - January 12 at 9:45 AM
Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain MomentumBristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
finance.yahoo.com - January 11 at 7:21 PM
Bristol-Myers Squibb Company (NYSE: BMY) Stock Sentiment Check: What Does Wall Street Say?Bristol-Myers Squibb Company (NYSE: BMY) Stock Sentiment Check: What Does Wall Street Say?
stocksregister.com - January 11 at 2:21 PM
Bristol Myers Squibb (BMY) Recently Broke Out Above the 200-Day Moving AverageBristol Myers Squibb (BMY) Recently Broke Out Above the 200-Day Moving Average
finance.yahoo.com - January 11 at 12:00 PM
Biomica/Bristol Myers on go with Phase I study of BMC-128 + Opdivo in cancerBiomica/Bristol Myers on go with Phase I study of BMC-128 + Opdivo in cancer
seekingalpha.com - January 11 at 9:21 AM
Evotec Gets $15 Mln From Bristol Myers Squibb On Expansion Of Neuroscience CollaborationEvotec Gets $15 Mln From Bristol Myers Squibb On Expansion Of Neuroscience Collaboration
nasdaq.com - January 11 at 4:13 AM
Whats Happening With Bristol Myers Squibb Stock?What's Happening With Bristol Myers Squibb Stock?
nasdaq.com - January 11 at 4:13 AM
PRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approachPRESS RELEASE: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
finanztreff.de - January 11 at 1:59 AM
DGAP-News: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approachDGAP-News: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
markets.businessinsider.com - January 11 at 1:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.